Guerbet Boston Consulting Group Matrix
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Guerbet Bundle
Actionable Strategy Starts Here
Curious where Guerbet’s products land—Stars, Cash Cows, Dogs or Question Marks? This snapshot teases the story; the full Guerbet BCG Matrix gives quadrant-by-quadrant placement, data-backed recommendations, and a clear playbook for investment and divestment. Buy the complete report for a Word deep dive plus an Excel summary you can present and act on—fast, practical, and built for decision-makers.
Stars
Elucirem (gadopiclenol) MRI
Elucirem (gadopiclenol) sits squarely in the Star box: it addresses a high-growth MRI contrast segment (global MRI contrast market CAGR ~6% projected 2024–2030) with a best-in-class relaxivity profile that delivers pronounced image enhancement, driving strong clinical buzz and rapid uptake in premium imaging sites. It is grabbing share quickly where performance matters, but needs heavy medical education, robust post-marketing data and access work to sustain momentum; keep fueling it — this can mature into a major cash engine as the market steadies.
Dotarem franchise in fast-growth markets
In emerging regions Dotarem retains leader status as a macrocyclic gadoterate agent (FDA approval 2013) while MRI capacity expands rapidly—regional MRI device instalments growing an estimated 8–10% annually in 2024. Its strong safety profile and brand trust convert well as exam volumes rise, but defending tenders requires sustained commercial push and targeted pricing. Hold share now and as growth tapers the franchise transitions into a predictable cash cow.
Integrated injection platforms + software
Integrated injection platforms plus software form a hardware–software–consumables loop that locks in sites and follows the imaging market’s ~5.6% CAGR (2024–30), driving utilization and share as volumes rise. Capex-heavy to seed and train, the business yields sticky recurring consumables and service revenue; Guerbet, with ~1.06bn EUR 2023 sales, should keep investing in workflow, interoperability and the data layer to defend the beachhead.
Interventional imaging solutions (oncology focus)
Interventional imaging is structurally expanding alongside liver oncology and minimally invasive procedures; the interventional radiology market was ~USD 11.6B in 2023 and HCC accounted for 905,677 new cases in 2020, driving procedural volumes where Guerbet’s enhanced visualization and delivery solutions convert higher procedure counts into market share.
Clinical support and KOL training are primary growth levers; alignment with guideline-driven outcomes and real-world evidence cements leadership as adoption and repeat use rise.
- IR market ~USD 11.6B (2023)
- HCC incidence 905,677 new cases (2020)
- Levers: clinical support, KOL training, guideline/outcomes alignment
Strategic hospital partnerships
Long-term supply and service bundles in top health systems scale rapidly once embedded, with multi-year contracts (3–7 years) delivering roughly 30–50% greater revenue visibility and utilization predictability for vendors. As networks standardize protocols, preferred-vendor status locks market share and reduces churn. Set-up costs are real, so double down on multi-year value contracts and joint continuous-improvement plans to secure volume.
- Scale: rapid uptake in consolidated systems
- Lock-in: standardized protocols = preferred-vendor advantage
- Investment: absorb set-up costs for predictable volume
- Action: pursue 3–7 year contracts + joint improvement KPIs
Premium MRI contrast: high-growth market (~6% CAGR) — back access, KOLs, long contracts
Elucirem is a Star: premium MRI contrast in a ~6% CAGR global MRI market (2024–30) with rapid uptake; requires continued med-ed, RWE and access investment to scale. Dotarem holds regional leadership as capacity grows (~8–10% installs 2024 ME/EMEA). Invest in integrated platforms, KOLs and multi-year contracts to lock durable share.
| Asset | Role | Growth/Metric | 2023/24 |
|---|---|---|---|
| Elucirem | Star | MRI market CAGR | ~6% (2024–30) |
| Guerbet | Investor | Sales | €1.06bn (2023) |
| IR | Adj. growth | Market size | USD 11.6B (2023) |
What is included in the product
Detailed Word Document
BCG analysis of Guerbet's portfolio: spots Stars, Cash Cows, Question Marks and Dogs with clear invest, hold or divest guidance.
Customizable Excel Spreadsheet
One-page BCG matrix for Guerbet, highlights portfolio pain points and prioritizes fixes for faster decisions.
Cash Cows
Xenetix (iodinated CT)
Xenetix is a mature iodinated CT agent with a broad label and dependable volumes, reflecting that iodinated agents still represent over 90% of CT contrast use in 2024. Pricing is disciplined, tenders are established terrain and operations run efficiently, so promotional spend can stay modest while service reliability remains key. Strategy: milk margins, safeguard supply continuity, and steer clear of unnecessary price wars.
Optiray (ioversol) CT
Optiray (ioversol) is an established CT contrast brand in a slow-growth CT market, maintaining steady share through long-standing clinical familiarity and high formulary retention. Its cash generation remains strong relative to modest reinvestment needs, supporting margin stability and free cash flow. Prioritize quality maintenance, secure long-term supply and purchasing contracts, and channel surplus cash to fund higher-growth pipeline projects.
Dotarem in mature markets
Dotarem, a macrocyclic gadolinium-based MRI contrast agent established across US and EU markets, now sits past its steep growth phase and is recognized for stability and clinical trust.
It continues to generate steady cash flow despite newer MRI agents gaining attention, supported by minimal promotion and emphasis on access and reliable supply.
Guerbet directs those cash flows toward next-generation MRI agents and digital solutions, funding R&D and commercialization efforts.
Lipiodol niche indications
Lipiodol serves a smaller, highly specialized cash cow within Guerbet: resilient and profitable through niche indications such as transarterial chemoembolization for hepatocellular carcinoma and lymphography. Clinical utility keeps it relevant without heavy marketing spend; demand is predictable while supply assurance is the operational focus. Compliance and clean margins are critical to sustain cash generation.
- Used in TACE and lymphography
- Supports stable niche revenues
- Demand predictable; prioritize supply security
- Tight compliance to protect margins
- HCC incidence ~905,677 new cases (IARC 2020)
Disposables and service contracts
Disposables and service contracts deliver recurring, high-margin revenue for Guerbet; the group reported ~€1.15bn revenue in 2023, with consumables and services a core cash engine. Growth is low but churn remains minimal once platforms are installed, making forecasting straightforward. Promotion needs are light; focus is logistics and pricing to boost incremental cash.
- Recurring revenue
- High margin
- Low growth, low churn
- Easy forecasting
- Optimize logistics/pricing
CT iodinated >90% dominance funds €1.15bn R&D pivot to next‑gen MRI
Xenetix and Optiray are mature iodinated CT cash cows (iodinated >90% of CT contrast use in 2024), Dotarem is a stable MRI cash generator, Lipiodol is a niche high-margin product, and disposables/services provide recurring cash; Guerbet reported ~€1.15bn revenue in 2023 and directs cash to next-gen MRI and digital R&D.
| Product | Role | Metric |
|---|---|---|
| Xenetix/Optiray | CT cash cows | iodinated >90% (2024) |
| Dotarem | MRI cash flow | stable |
| Lipiodol | Niche cash | HCC incidence 905,677 (IARC 2020) |
| Consumables/Services | Recurring revenue | Guerbet €1.15bn (2023) |
Preview = Final Product
Guerbet BCG Matrix
The file you're previewing is the exact Guerbet BCG Matrix you'll receive after purchase—no watermarks, no placeholders. It's fully formatted and analysis-ready, built from market insights specific to Guerbet. No revisions needed. Buy and download instantly; it's editable, printable, and ready to present to stakeholders without surprises.
Dogs
Legacy software modules with low uptake
Nice-to-have legacy modules that never hit critical mass continue to soak up support dollars. Growth is flat and switching costs aren’t saving them. Hard to justify roadmap spend—Gartner 2024 forecasts global IT spending of $4.7 trillion while enterprises spend up to 70% of software budgets on maintenance. Sunset gracefully or bundle only when necessary.
Older injector SKUs in crowded niches
Older injector SKUs sit in crowded niches and have been outpaced by newer models and competitors with sharper ergonomics, leaving only trickle sales while tying up resources in maintenance and spare parts. Turnarounds for these platforms are typically costly and deliver limited upside, eroding margin and distracting R&D and commercial teams. Rationalize the line, discontinue nonstrategic units, and redirect effort toward higher-growth, ergonomically superior models and aftermarket services.
Commodity tenders where share is tiny
Price-only commodity tenders where Guerbet holds a tiny share typically compress margins to low single digits (around 1–3%) and deliver sub-2% volume growth in 2024; entrenched rivals extend procurement cycles, consuming commercial time and eroding ROI. Winning isolated bids rarely moves consolidated revenue (often <1–3% of total), creating cash traps in slow-growth zones; exit or sharply narrow participation criteria to protect margin and free up resources.
Fragmented distributor micro-markets
Fragmented distributor micro-markets: small geographies with low control and limited Guerbet brand pull produce lumpy revenue while fixed support costs persist, creating negative ROI and distraction from core channels. Consolidate partners or divest the tail to free sales and marketing resources and reduce complexity.
- Low control
- Lumpy revenue
- High support cost
- Consolidate/divest
Obsolescent SKUs pressured by regulation
Obsolescent SKUs require compliance upgrades in 2024 whose implementation costs exceed the incremental revenue they generate, while market demand continues to decline; sustaining them diverts QA and supply-chain bandwidth from higher-growth contrast agents. Retire these SKUs and reallocate capacity toward core MRI/CT contrast lines to boost ROI and operational focus.
- 2024: compliance cost > SKU revenue
- Demand trending down
- QA/supply tied up
- Retire & reallocate capacity
Rationalize tail SKUs: cut 1-3% margin dogs - fund MRI/CT injectors
Legacy modules, obsolescent SKUs and low-share commodity tenders deliver flat/sub-2% growth, 1–3% margins, and consume QA/support spend; 2024 compliance costs often exceed SKU revenue. Rationalize/discontinue tail SKUs and micro-markets; reallocate spend to core MRI/CT contrast and high-growth injectors.
| Metric | 2024 |
|---|---|
| Growth | ~0–2% |
| Margin (dogs) | 1–3% |
| Revenue share | <1–3% |
| Gartner IT spend | $4.7T |
Question Marks
AI-enabled imaging workflow
Clinical interest in AI-enabled imaging workflows is high but Guerbet’s market share is still early in a crowded AI-imaging segment valued at over $1B in 2024 and growing at >25% CAGR. If the solution scales via injector integration and data platforms it can flip to a Star, but it requires clear ROI proofs and hospital IT wins (many hospitals prioritized AI pilots in 2024). Decide quickly: invest to drive ecosystem pull, or partner and keep exposure light.
Next-gen low-dose iodinated concepts
Next‑gen low‑dose iodinated concepts present a promising clinical angle given ~80 million CT scans/year in the US alone, but commercial traction remains unproven. Adoption can accelerate if efficacy, safety, and cost-effectiveness hit payor thresholds (commonly $50,000–$150,000 per QALY). Ongoing Phase II/III trials, robust health‑economic models, and access pathways will determine uptake. Fund to key value inflection (trial readouts, cost‑effect evidence), then reassess.
Radiopharma/theranostics plays
Radiopharma/theranostics is a high-growth adjacency (global radiopharmaceuticals market CAGR ~10.5%, projected to reach about $9.6B by 2030) but faces steep regulatory, production and distribution hurdles and heavyweight rivals such as Novartis, Bayer and Curium. Early share for Guerbet would be small while capex and clinical development often exceed several hundred million dollars. Strategic fit with imaging is strong, so focus is critical: co-develop with a specialist partner or divest the opportunity.
Expansion in China/India MRI/CT
Expansion in China/India MRI/CT: volumes surged in 2024 against large patient pools (China ~1.425B, India ~1.428B), but local OEMs and aggressive pricing compress margins; share is still forming with material upside if public-tender and hospital contract wins land. Success requires local manufacturing, tender expertise, and KOL backing; pursue bold, province-focused rollouts rather than nationwide proliferation.
- Market context: large 2024 patient pools enable scale
- Challenges: fierce local competition, price pressure
- Requirements: local MFG, tender savvy, KOL support
- Strategy: concentrate investment in select provinces/metros
Sustainability and contrast waste solutions
Question Marks: Sustainability and contrast waste solutions face nascent adoption despite hospitals seeking greener pathways; healthcare contributes about 4.4% of global CO2 emissions (Lancet 2019), creating regulatory and reputation pressure that can drive uptake if tied to compliance and direct cost savings. Pilots with clear KPIs, simple ops and proof points are required; package as service contracts, then scale through procurement cycles.
Pilot to de-risk, fund to inflection, chase AI & radiopharma upside, then scale or divest
Question Marks: several adjacencies (AI imaging >$1B 2024, +25% CAGR; low‑dose iodinated—80M US CTs/yr; radiopharma market ~$3.4B 2024, ~10.5% CAGR) show high upside but low Guerbet share and high investment/risk. Prioritize pilots to de‑risk, fund to inflection (trial readouts, IT wins), then scale or divest.
| Opportunity | 2024 Size | CAGR | Barrier |
|---|---|---|---|
| AI imaging | $1B | 25% | ROI/IT wins |